DGAP-News

PAION AG: ACACIA PHARMA LAUNCHES BYFAVO(TM) (REMIMAZOLAM) IN THE U.S. FOR PROCEDURAL SEDATION IN ADULTS UNDERGOING MEDICAL PROCEDURES LASTING 30 MINUTES OR LESS - Seite 2

Dr. Jim Phillips, Chief Executive Officer of PAION AG, stated: "We are excited to support Acacia in their commercialization process, and we are delighted by the strong commitment to BYFAVO(TM) by our U.S. partner. As sales build through the next months and years PAION will be receiving royalties of between 20-25% in the U.S. We look forward to a successful launch of what is a unique new product entering the market."

Mike Bolinder, Acacia Pharma's CEO, commented: "We are delighted to make BYFAVO(TM) available to anesthesia providers and to the millions of patients across the U.S. who require moderate sedation to undergo medical procedures each year. BYFAVO(TM) and BARHEMSYS^(R) have a clear and shared value proposition focused on safely and rapidly mobilizing patients after such procedures, which drives revenues of hospitals and surgical centers in the U.S. The launches come at a time when Covid-19 has had a significant impact on such centers, creating significant patient backlogs and impacting ongoing revenues. We believe our products can help improve patient throughput, which is now even more relevant for healthcare providers and their patients. We believe that the ability to help address the current backlog of elective surgeries, together with ongoing shortages for existing drugs in these therapeutic areas, puts Acacia Pharma in a strong position as the Company enters these markets."

Mr. Bolinder added: "It is a tremendous achievement for our company to gain approval and launch two new products in the U.S. within the course of the last year. I would like to thank PAION, our partners as well as the Acacia Pharma team and our stakeholders who have enabled us to bring this new and innovative therapeutic to market, particularly given the challenges caused by the pandemic over the past year."

BYFAVO(TM) is now available for ordering in the U.S. through the major wholesalers and selected specialty distributors, including Cardinal Health, Amerisource Bergen, Besse, McKesson, McKesson Medsurg, Morris and Dickson, and Curascript.

###

About remimazolam
Remimazolam is an ultra-short-acting intravenous benzodiazepine sedative/anesthetic. In the human body, remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and is not metabolized by cytochrome-dependent hepatic pathways. Like other benzodiazepines, remimazolam can be reversed with flumazenil to rapidly terminate sedation or anesthesia if necessary. Data so far indicate that remimazolam has a rapid onset and offset of action combined with a favorable cardio-respiratory safety profile.